Supplemental Online Content

Ramagopalan SV, Popat S, Gupta A, et al. Transportability of overall survival estimates from US to Canadian patients with advanced non–small cell lung cancer with implications for regulatory and health technology assessment. *JAMA Netw Open*. 2022;5(11):e2239874. doi:10.1001/jamanetworkopen.2022.39874

**eTable.** Baseline Patient Characteristics of the Second-Line Docetaxel Group

**eFigure.** Kaplan-Meier Curves for Second-Line Docetaxel Monotherapy

This supplemental material has been provided by the authors to give readers additional information about their work.
**eTable.** Baseline Patient Characteristics of the Second-Line Docetaxel Group

| Category                        | 2L docetaxel |
|---------------------------------|--------------|
| Sample size                     | 301          | 138          |
| Age at index date (mean (SD))   | 65.00 (9.52) | 63.53 (8.67) | 0.161       |
| Sex (%)                         | Female       | 130 (43.2)   | 68 (49.3)   | 0.123       |
|                                 | Male         | 171 (56.8)   | 70 (50.7)   |
| Cancer stage at diagnosis (%)   | IIb/IIlc     | 30 (10.0)    | 23 (16.7)   | 0.198       |
|                                 | IV           | 271 (90.0)   | 115 (83.3)  |
| ECOG PS (%)                     | 0-1          | 223 (74.1)   | N/A         |
|                                 | 2+           | 78 (25.9)    | N/A         |
| Tumor histology (%)             | Non-squamous cell carcinoma | 227 (75.4) | 92 (66.7) | 0.193 |
|                                 | Squamous cell carcinoma | 74 (24.6)   | 46 (33.3)   |
| Smoking history (%)             | Ever         | 282 (93.7)   | 126 (91.3)  | 0.091       |
|                                 | Never        | 19 (6.3)     | 12 (8.7)    |
| Time from diagnosis to index date (months) (median [IQR]) | 6.67 [4.41, 9.37] | 10.13 [7.17, 15.58] | 0.702 |
| Time since 2011-01-01 (years) (median [IQR]) | 3.50 [2.65, 4.24] | 5.33 [3.86, 8.03] | 0.783 |
| Comorbidities (%)               | 0            | 231 (76.7)   | N/A         | N/A         |
|                                 | 1+           | 70 (23.3)    | N/A         |
| Number of sites of metastases   | 0-1          | 247 (82.1)   | N/A         | N/A         |
|                                 | 2+           | 54 (17.9)    | N/A         |
eFigure. Kaplan-Meier Curves for Second-Line Docetaxel Monotherapy

The number of patients at risk (US) were n = 541 - 147 - 62 - 39 - 27 - 20 - 12 and (Canada) 138 - 39 - 13 - 6 - 5 - 4 - 3 at every 10-month interval beginning with time zero until month 60 of follow-up.